Bapineuzumab: Phase III Trial Information

Contributed by: Dennis Fortier, President, Medical Care Corporation
________________________________________________

A Phase III clinical trial for Bapineuzumab, described in an earlier post, is open and enrolling patients.

The study is seeking subjects aged 50 to 88 with a diagnosis of probable AD. Importantly, subjects will also need a caregiver who is willing to be meaningfully involved in the study.

This drug is administered intravenously and the study protocol calls for 15 infusions over a 65 week period. More details are available here.